Optimal Testing of the Live Organ Donor for Blood-Borne Viral Pathogens: The Rep

[Clark]

http://onlinelibrary.wiley.com/doi/10.1111/ajt.12205/abstract

Optimal Testing of the Live Organ Donor for Blood-Borne Viral Pathogens: The Report of a Consensus Conference
E. A. Blumberg1,*, M. G. Ison2, T. L. Pruett3, D. L. Segev4, on behalf of the Optimal Testing of the Live Organ Donor Consensus Conference Participants
DOI: 10.1111/ajt.12205
American Journal of Transplantation
Volume 13, Issue 6, pages 1405–1415, June 2013

Abstract
In 2011, live donor transmission events involving Human Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) prompted consideration of changing the process of live donor testing and evaluation in the United States. Following CDC recommendations for screening all live donors with nucleic acid testing for HIV, HCV and Hepatitis B (HBV), a consensus conference was convened to evaluate this recommendation. Workgroups focused on determining whether there was an evidence based rationale for identifying live donors at increased risk for HIV, HBV and HCV, testing options and timing for diagnosing these infections in potential donors and consent issues specific to potential increased risk donor utilization. Strategies for donor assessment were proposed. Based on review of the limited available evidence as well as guidance documents and policies currently in place in the United States and other countries, the conference participants recommended that HIV, HBV and HCV NAT should not be required for live donor evaluation; the optimal timing of live donor testing for these blood borne pathogens has not been determined.